141 related articles for article (PubMed ID: 16728689)
41. Regulation of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and extracellular metalloproteinase inducer by interleukin-17 in human periodontal ligament fibroblasts.
Wu Y; Zhu L; Wei H; Peng B
J Endod; 2013 Jan; 39(1):62-7. PubMed ID: 23228259
[TBL] [Abstract][Full Text] [Related]
42. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke.
Kouwenhoven M; Carlström C; Ozenci V; Link H
J Clin Immunol; 2001 Sep; 21(5):365-75. PubMed ID: 11720009
[TBL] [Abstract][Full Text] [Related]
43. Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha.
Meller D; Li DQ; Tseng SC
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):2922-9. PubMed ID: 10967046
[TBL] [Abstract][Full Text] [Related]
44. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
45. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque.
Chen F; Eriksson P; Hansson GK; Herzfeld I; Klein M; Hansson LO; Valen G
Int J Mol Med; 2005 Jan; 15(1):57-65. PubMed ID: 15583828
[TBL] [Abstract][Full Text] [Related]
46. Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by Porphyromonas gingivalis in an engineered human oral mucosa model.
Andrian E; Mostefaoui Y; Rouabhia M; Grenier D
J Cell Physiol; 2007 Apr; 211(1):56-62. PubMed ID: 17226791
[TBL] [Abstract][Full Text] [Related]
47. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
48. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
Horstmann S; Kalb P; Koziol J; Gardner H; Wagner S
Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822
[TBL] [Abstract][Full Text] [Related]
49. EFFECT OF RELATIVE GENE EXPRESSION ON PLAQUE VULNERABILITY IN PATIENTS WITH STABLE ANGINA AND PATIENTS WITH ACUTE CORONARY SYNDROME.
Chen N; Zhang JY; Yang SZ; Li YD
J Biol Regul Homeost Agents; 2015; 29(2):437-41. PubMed ID: 26122234
[TBL] [Abstract][Full Text] [Related]
50. Imbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury.
Mazanowska O; Kamińska D; Krajewska M; Zabińska M; Kopeć W; Boratyńska M; Chudoba P; Patrzalek D; Klinger M
Transplant Proc; 2011 Oct; 43(8):3000-3. PubMed ID: 21996210
[TBL] [Abstract][Full Text] [Related]
51. Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment.
Seitz M; Dayer JM
Rheumatology (Oxford); 2000 Jun; 39(6):637-45. PubMed ID: 10888709
[TBL] [Abstract][Full Text] [Related]
52. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
53. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms.
Zhang Y; McCluskey K; Fujii K; Wahl LM
J Immunol; 1998 Sep; 161(6):3071-6. PubMed ID: 9743373
[TBL] [Abstract][Full Text] [Related]
54. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
55. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
[TBL] [Abstract][Full Text] [Related]
56. Matrix metalloproteinases and their inhibitors in the nasal mucosa of patients with perennial allergic rhinitis.
Shaida A; Kenyon G; Devalia J; Davies RJ; MacDonald TT; Pender SL
J Allergy Clin Immunol; 2001 Nov; 108(5):791-6. PubMed ID: 11692106
[TBL] [Abstract][Full Text] [Related]
57. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
[TBL] [Abstract][Full Text] [Related]
58. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
[TBL] [Abstract][Full Text] [Related]
59. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
